Vaxxinity UB-312 Parkinson’s Trial Results Published in Nature Medicine

June 20, 2024

UB-312 is the first Parkinson’s candidate to reduce pathology as measured by a seed amplification assay, and suggest clinical improvement on motor experiences of daily living.

Read more at globenewswire.com

Related news for (VAXX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.